使用商用人工智能乳腺X线分析软件改善乳腺超声解读
该回顾性研究纳入1109个同时接受乳腺X线和超声引导下活检的乳腺,评估商用AI乳腺X线分析软件鉴别良性转归与超声引导下活检证实癌症的性能。AI评分鉴别良恶性的AUROC为0.79(95%CI 0.79-0.82);整合AI评分的预测模型在开发队列和验证队列的AUROC分别为0.85(95%CI 0.81-0.88)和0.84(95%CI 0.79-0.90),均优于非AI模型(P<0.001)。
要点
- 商用AI乳腺X线分析软件鉴别超声引导下活检良恶性转归的AUROC为0.79(95%CI 0.79-0.82)。
- 整合AI评分的预测模型在开发队列AUROC为0.85(95%CI 0.81-0.88),验证队列为0.84(95%CI 0.79-0.90)。
- 整合模型在开发队列和验证队列均优于非AI模型(P<0.001)。
核心结论
- 商用AI乳腺X线分析软件可能作为临床决策的有价值辅助工具,用于管理超声发现的乳腺病灶。
研究设计与样本
- 回顾性分析纳入1109个同时接受乳腺X线和超声引导下乳腺活检的乳腺,AI软件处理乳腺X线片并给出0至100的AI评分表示恶性可能性;采用逻辑回归构建含与不含AI评分的良性转归预测模型。
诊断标准与关键数值
- AI评分鉴别超声引导下活检良性转归与癌症的AUROC为0.79(95%CI 0.79-0.82)。非AI模型、仅AI模型、整合AI模型在开发队列的AUROC分别为0.79(95%CI 0.75-0.83)、0.78(95%CI 0.74-0.82)、0.85(95%CI 0.81-0.88)。非AI模型、仅AI模型、整合AI模型在验证队列的AUROC分别为0.75(95%CI 0.68-0.81)、0.82(95%CI 0.76-0.88)、0.84(95%CI 0.79-0.90)。
临床应用与阅片要点
- 作者指出该商用AI乳腺X线分析软件可能作为临床决策的有价值辅助工具,用于管理超声发现的乳腺病灶,并可能减少不必要的活检和改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the use of a commercial artificial intelligence (AI)-based mammography analysis software for improving the interpretations of breast ultrasound (US)-detected lesions.
METHODS: A retrospective analysis was performed on 1109 breasts that underwent both mammography and US-guided breast biopsy. The AI software processed mammograms and provided an AI score ranging from 0 to 100 for each breast, indicating the likelihood of malignancy. The performance of the AI score in differentiating mammograms with benign outcomes from those revealing cancers following US-guided breast biopsy was evaluated. In addition, prediction models for benign outcomes were constructed based on clinical and imaging characteristics with and without AI scores, using logistic regression analysis.
RESULTS: The AI software had an area under the receiver operating characteristics curve (AUROC) of 0.79 (95% CI, 0.79-0.82) in differentiating between benign and cancer cases. The prediction models that did not include AI scores (non-AI model), only used AI scores (AI-only model), and included AI scores (integrated model) had AUROCs of 0.79 (95% CI, 0.75-0.83), 0.78 (95% CI, 0.74-0.82), and 0.85 (95% CI, 0.81-0.88) in the development cohort, and 0.75 (95% CI, 0.68-0.81), 0.82 (95% CI, 0.76-0.88), and 0.84 (95% CI, 0.79-0.90) in the validation cohort, respectively. The integrated model outperformed the non-AI model in the development and validation cohorts (p < 0.001 for both).
CONCLUSION: The commercial AI-based mammography analysis software could be a valuable adjunct to clinical decision-making for managing US-detected breast lesions.
CLINICAL RELEVANCE STATEMENT: The commercial AI-based mammography analysis software could potentially reduce unnecessary biopsies and improve patient outcomes.
KEY POINTS: • Breast US has high rates of false-positive interpretations. • A commercial AI-based mammography analysis software could distinguish mammograms having benign outcomes from those revealing cancers after US-guided breast biopsy. • A commercial AI-based mammography analysis software may improve interpretations for breast US-detected lesions.
引用
- Kim HJ, Kim HH, Kim KH, et al. Use of a commercial artificial intelligence-based mammography analysis software for improving breast ultrasound interpretations. Eur Radiol. 2024. PMID: 38570382. doi:10.1007/s00330-024-10718-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。